Abbott Makes Three, Not Two, Investments In AFib Ablation
This article was originally published in The Gray Sheet
Abbott made a minority equity investment in VytronUS as part of the startup's latest funding round, according to the VytronUS' biggest institutional investor. That comes in addition to an acquisition and a right-to-purchase transaction for two other atrial fibrillation ablation firms, marking Abbott's entry into that market.
You may also be interested in...
The diversified company is entering the atrial fibrillation catheter ablation for the first time. It is acquiring Afib ablation mapping system maker Topera and has gained rights to buy catheter developer Advanced Cardiac Therapeutics.
The cardiac arrhythmia ablation device firm raised $31.6 million in a Series B financing, the same day its CEO was announced to be leaving for Abbott's new electrophysiology unit.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.